IQVIA Holdings Inc. $IQV Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 61,416 shares of the medical research company’s stock after selling 3,582 shares during the quarter. Victory Capital Management Inc.’s holdings in IQVIA were worth $11,665,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Physician Wealth Advisors Inc. increased its holdings in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares in the last quarter. Westside Investment Management Inc. raised its position in shares of IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in shares of IQVIA during the third quarter valued at $36,000. Root Financial Partners LLC purchased a new position in IQVIA in the 3rd quarter worth about $43,000. Finally, Hantz Financial Services Inc. raised its holdings in IQVIA by 92.0% during the 3rd quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock worth $46,000 after buying an additional 115 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on IQV shares. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research report on Friday, March 6th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. UBS Group reduced their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. BMO Capital Markets set a $250.00 price target on IQVIA in a report on Friday, February 6th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Trading Up 0.4%

IQVIA stock opened at $171.64 on Thursday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The company’s fifty day simple moving average is $204.05 and its 200-day simple moving average is $207.14. The stock has a market cap of $29.13 billion, a P/E ratio of 21.84, a P/E/G ratio of 1.65 and a beta of 1.39.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the previous year, the company posted $3.12 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.